“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Mumbai, Baltimore, November 24, 2015: Pharma Major Lupin Limited (Lupin) announced today that it has received final approvals for its Blisovi® Fe 1/20 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) and Blisovi® 1.5/30 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg) from the United States Food and Drug Administration (FDA) to market generic versions of Warner Chilcott's Loestrin® Fe 1/20 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) and Loestrin® Fe 1.5/30 Tablets (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg). Lupin's US subsidiary, Lupin Pharmaceuticals Inc. shall commence promoting the product in the US shortly.
Lupin's Blisovi® Fe 1/20 Tablets and Blisovi® 1.5/30 Tablets are the AB rated generic equivalent of Warner Chilcott's Loestrin® Fe 1/20 Tablets and Loestrin® Fe 1.5/30 Tablets and are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Loestrin® Fe 1/20 had US sales of USD 139.7 million (IMS MAT September 2015) while Loestrin® Fe 1.5/30 had US sales of USD 55.5 million (IMS MAT September 2015).
About Lupin Limited Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Lupin is the 6th largest and fastest growing top 10 generics player in the US (5.5% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th - IMS Health). For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were . 125,997 million (USD 2.06 billion) and . 24,032 million (USD 393 million) respectively.
About Lupin Pharmaceuticals Inc. (LPI)
Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies.
Please visithttp://www.lupin.com for more information. You could also follow us on Twitter - www.twitter.com/lupinlimited CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098
For more information, please contact -
Shamsher Gorawara Head - Corporate Communications Ph: +91-22- 98 20 338 555 Email: shamshergorawara@lupin.com
or
Alpesh Dalal Head - M & A and Investor Relations Lupin Limited Ph: +91 98 20 023 511 Email: alpeshdalal@lupin.com
Safe Harbor Statement
